The federal government has given permission to the pharmaceutical companies to increase the prices of 94 lifesaving drugs in order to end the shortage of drugs in the market.
Special Assistant to Prime Minister on National Health Services Dr. Faisal Sultan, “To address the long-term shortage of some key or lifesaving medicines, the federal cabinet has allowed rationalizing prices of drugs that had been reported to be in short supply due to unrealistically low prices.”
This was revealed by Dr. Faisal Sultan in a press conference with Federal Minister for Information Shibli Faraz.
As per SAPM, the prices were increased for the drugs in the “hardship category”. They were increased on Drug Pricing Committee recommendation under the Drugs Pricing Policy of 2018.
Dr. Sultan said that this decision has been taken in order to end the inaccessibility of drugs in the market because of unrealistic prices. The aim is to make sure these drugs are locally available instead of being sold at high prices via unregulated channels.
The drugs whose prices have increased include furosemide injections for emergency use, acetazolamide medicine for glaucoma; hydralazine tablets for reducing the blood pressure, carbamazepine tablets suspension for epilepsy, atropine sulphate injection, magnesium sulphate to cure seizures, hydroxyurea, daunorubicin, bleomycin used in cancer treatment, nitroglycerin and glyceryl trinitrate used as heart medicines, and anti-rabies vaccine.